The Effect of Intravitreal Bevacizumab Injection in Wet Age-Related Macular Degeneration Patients with Cataract Surgery

This study was design to evaluate the efficacy of cataract surgery with simultaneous intravitreal bevacizumab injection for wet age-related macular degeneration. Of patients who underwent anti-vascular endothelial growth factor injections, performed in 24 eyes (control group), and 27 (bevacizumab group). Best corrected visual acuity, ocular tonometry, anterior chamber inflammation, central subfield thickness were measured at baseline 1 week, month, 3 months, 6 months after surgery. The mean increased month postoperatively control group (<i>p</i> = 0.02), whereas there no significant change group. When preoperative postoperative differences between two groups compared each time point, best acuity improved 0.045), more decreased that 0.032). Additional 1.56 ± 2.05 2.52 2.01 groups, respectively 0.047). Simultaneous is considered an effective treatment since it reduces short term, can delay timing additional injections